Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 known ✓ | Q99720 | 2/20 | 0.56 |
| ▸ | MAOB known ✓ | P27338 | 2/20 | 0.50 |
| ▸ | MAOA known ✓ | P21397 | 1/20 | 0.50 |
| ▸ | GLA known ✓ | P06280 | 1/20 | 0.47 |
| ▸ | ACHE known ✓ | P22303 | 4/20 | 0.46 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.62 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.62 |
| ▸ | PRMT8 | Q9NR22 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.53 |
| ▸ | LMNA | P02545 | 4/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.53 |
| ▸ | BLM | P54132 | 1/20 | 0.53 |
| ▸ | TSHR | P16473 | 5/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.50 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.48 |
| ▸ | TP53 | P04637 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | HBB | P68871 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL11109064 | 1.00 | CARM1 (0.62) | CARM1PRMT6PRMT8SIGMAR1ALDH1A1 | |
| SCHEMBL2001215 | 0.98 | CARM1 (0.64) | CARM1PRMT6PRMT8SIGMAR1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL3642056 | 0.91 | CARM1 (0.53) | CARM1PRMT6PRMT8SIGMAR1ALDH1A1 | |
| Hydrochloric Acid SCHEMBL1593475 | 0.88 | SIGMAR1 (0.62) | CARM1PRMT6PRMT8SIGMAR1ALDH1A1 | |
| SCHEMBL2058653 | 0.86 | SIGMAR1 (0.65) | CARM1PRMT6PRMT8SIGMAR1ALDH1A1 | |
| SCHEMBL7055109 | 0.84 | CARM1 (0.75) | CARM1PRMT6PRMT8SIGMAR1ALDH1A1 | |
| SCHEMBL11203747 | 0.84 | SIGMAR1 (0.68) | CARM1PRMT6PRMT8SIGMAR1LMNA | |
| Hydrochloric Acid SCHEMBL1087168 | 0.83 | SIGMAR1 (0.71) | CARM1PRMT6PRMT8SIGMAR1ALDH1A1 | |
| SCHEMBL11872505 | 0.82 | SIGMAR1 (0.71) | CARM1PRMT6PRMT8SIGMAR1LMNA | |
| SCHEMBL11308286 | 0.82 | CARM1 (0.51) | CARM1PRMT6PRMT8SIGMAR1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 80 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190100498-A1 | CRYSTALLINE FORM | ASTRAZENECA AB (SE) | 2019-04-04 | — | — | US | disclosed |
| EP-3233805-B1 | METHYL-1H-PYRAZOLE-ALKYLAMINE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN | ESTEVE PHARMACEUTICALS SA (ES) | 2019-02-06 | — | — | EP | disclosed |
| EP-3433237-A1 | CRYSTALLINE FORM | Astrazeneca AB (SE) | 2019-01-30 | — | — | EP | disclosed |
| US-10071968-B2 | Methyl-1H-pyrazole alkylamine compounds having multimodal activity against pain | ESTEVE PHARMACEUTICALS S.A. (ES) | 2018-09-11 | — | — | US | disclosed |
| US-20170305862-A1 | METHYL-1H-PYRAZOLE ALKYLAMINE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN | ESTEVE PHARMACEUTICALS, S.A. (ES) | 2017-10-26 | — | — | US | disclosed |
| WO-2017162304-A1 | CRYSTALLINE FORM | ASTRAZENECA AB (SE) | 2017-09-28 | — | — | WO | disclosed |
| EP-2432768-B1 | NOVEL PYRIMIDINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF CANCER AND FURTHER DISEASES | SUMITOMO DAINIPPON PHARMA CO LTD (JP) | 2017-07-05 | — | — | EP | disclosed |
| US-9533978-B2 | Pyrimidine derivatives and their use in the treatment of cancer and further diseases | SUMITOMO DAINIPPON PHARMA CO., LTD (JP) | 2017-01-03 | — | — | US | disclosed |
| US-20150080396-A1 | Novel Pyrimidine Derivatives and Their Use in the Treatment of Cancer and Further Diseases | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2015-03-19 | — | — | US | disclosed |
| CN-102216302-B | Akt and p70 s6 kinase inhibitors | LILLY CO ELI | 2013-08-21 | — | — | CN | disclosed |
| EP-0042054-B1 | 1-AMINO-3-PHENYL INDOLES, THEIR SALTS AND MEDICAMENTS CONTAINING THEM | SIEGFRIED AKTIENGESELLSCHAFT (CH) | 1985-07-31 | — | — | EP | disclosed |
| EP-0042054-A1 | 1-Amino-3-phenyl indoles, their salts and medicaments containing them | SIEGFRIED AKTIENGESELLSCHAFT (CH) | 1981-12-23 | — | — | EP | disclosed |
| US-RE30739-E | ANTIDEPRESSANT | BEECHAM GROUP LIMITED (GB) | 1981-09-08 | — | — | US | disclosed |
| US-4167515-A | Anorexic chromans | BEECHAM GROUP LIMITED (GB) | 1979-09-11 | — | — | US | disclosed |
| US-4153617-A | Anorexic chromans | BEECHAM GROUP LIMITED (GB) | 1979-05-08 | — | — | US | disclosed |
| US-4148909-A | Chromans to treat depression and reduce appetite | BEECHAM GROUP LIMITED (GB) | 1979-04-10 | — | — | US | disclosed |
| US-4146539-A | MOOD MODIFYERS, ANTIDEPRESSANTS | BEECHAM GROUP LIMITED (GB) | 1979-03-27 | — | — | US | disclosed |
| US-4080335-A | Anorexic chromans | BEECHAM GROUP LIMITED (GB) | 1978-03-21 | — | — | US | disclosed |
| US-4016263-A | BACTERICIDES | BOEHRINGER INGELHEIM GMBH (DT) | 1977-04-05 | — | — | US | disclosed |
| US-3985730-A | 5-Alkyl-10-(aminocarbonyl/aminomethyl/cyano)-10,11-dihydro-5H-dibenz[b,f]azepine-10-alkanamines | G. D. SEARLE & CO. (US) | 1976-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170305862-A1 | METHYL-1H-PYRAZOLE ALKYLAMINE COMPOUNDS HAVING MULTIMODAL ACTIVITY AGAINST PAIN | OPRM1, OPRD1, OPRK1 | SIGMAR1 4/4885MAOB 732/4885MAOA 627/4885 |
| US-10071968-B2 | Methyl-1H-pyrazole alkylamine compounds having multimodal activity against pain | OPRM1, OPRD1, OPRK1 | SIGMAR1 4/4885MAOB 668/4885MAOA 580/4885 |
| US-20150080396-A1 | Novel Pyrimidine Derivatives and Their Use in the Treatment of Cancer and Further Diseases | TYMS, TYMP, DPYD | SIGMAR1 2242/4885MAOB 699/4885MAOA 1931/4885 |
| US-20190100498-A1 | CRYSTALLINE FORM | GYS2, PYGL, SFPQ | SIGMAR1 1498/4885MAOB 1305/4885MAOA 1914/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.